Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

April 6, 2018: By Jon Swedien

A first-in-kind stem cell–based retinal implant improved visual acuity or function in three of four subjects with advanced dry age-related macular degeneration (AMD) during a Phase I/IIa study, according to physicians and researchers at the USC Roski Eye Institute.

The treatment consisted of a layer of human embryonic stem cell-derived retinal pigment epithelium cells on an ultrathin supportive structure implanted in the retina, the university said. A USC Roski Eye Institute surgeon performed the surgeries on the four patients.

The treatment is designed to replace a single-cell layer that degenerates in patients with dry AMD, said lead author and surgeon for the study, Amir H. Kashani, MD, PhD.

Researchers followed the study’s four patients for up to one year to assess the implant’s safety. There were no severe adverse events related to the implant or the surgical procedure, the university said.

The research team also performed a preliminary assessment of the therapy’s efficacy.

One patient’s visual acuity improved by 17 letters. Two patients gained visual function, as measured by how well they could use the area of the retina treated by the implant, the university said.

None of the patients’ vision worsened, the university said. Researchers noted integration of the implant with photoreceptor cells in all patients.

The study results were published April 4 in Science Translational Medicine.

The study is titled “A Bioengineered Retinal Pigment Epithelial Monolayer for Advanced Dry Age Related-Macular Degeneration.”

It was funded in part by the California Institute for Regenerative Medicine, the university said. Regenerative Patch Technologies also contributed funding to the study.

Mark Humayun, MD, PhD, is the coauthor and lead inventor of the implant. Humayun also co-invented and co-developed the Argus II Retinal Prosthesis System with Second Sight Medical Products.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023